Aytül Önal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aytül Önal has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Sibel Ülker
Faculty of Medicine, Ege University
3 shared publications - Gulgun Sengul
Department of Anatomy, School of Medicine, Ege University, Izmir, Turkey
2 shared publications - Neslihan Düzenli
Izmir Democracy University School of Medicine
2 shared publications Akgün Evinç
Departments of Pharmacology
1 shared publication- Aysegul Keser
Department of Physiology, Faculty of Medicine, Ege University, Izmir 35100, Turkey
1 shared publication Ayşe Sürücü
Departments of Pharmacology
1 shared publication
Latest Publications
- Open Access
- 24 December 2024
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 26 (3) , 256-262
A MODIFICATION OF THE CHRONIC CONSTRICTION INJURY MODEL OF NEUROPATHIC PAIN: SILK USAGE INSTEAD OF CHROMIC CATGUT
Objective: In the chronic constriction injury (CCI) neuropathic pain rat model, usage of chromic catgut causes intense neuroinflammation and also undesirable conditions such as autotomy. This causes difficulties in the application and interpretation of pain behaviour tests. In this study, it was aimed to investigate the suitability of the use of surgical silk as a suture material in the CCI model, based on behavioural tests and certain biomarkers. Material and Methods: CCI model was created by loosely ligating the right sciatic nerves of rats with surgical silk. Tactile allodynia, thermal and mechanical hyperalgesia were evaluated on the 2nd, 7th, 14th, 21st and 29th postoperative days. Expressions of glial fibrillary acidic protein (GFAP), signal transducer and transcription activator 3 (STAT3) and its phosphorylated form (p-STAT3) were evaluated from the spinal cord tissue by western blotting technique. Results: Sciatic nerve-ligated rats did not lose weight but gained weight on days 14, 21, and 29 like control rats. Statistically significant decreases were found in pain thresholds in three different pain tests after the operation. The decrease in the pain threshold was accompanied by a statistically significant increase in GFAP protein expression in the spinal cord on days 2 and 14 simultaneously. No statistically significant difference was found in the expression of STAT3 or p-STAT3 protein in the spinal cord at any time. Conclusion: The absence of weight loss and autotomy expected from the classical CCI model, the reversal of the decrease in the pain threshold, the concomittant increase in GFAP protein expression in the spinal cord, and the absence of change in STAT3 and p-STAT3 expression in our study suggest that the model we created by tying 3 loose silk knots on the sciatic nerve has a milder course of neuroinflammation.
- 24 December 2024
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 26 (3) , 256-262
Open AccessA MODIFICATION OF THE CHRONIC CONSTRICTION INJURY MODEL OF NEUROPATHIC PAIN: SILK USAGE INSTEAD OF CHROMIC CATGUT
Objective: In the chronic constriction injury (CCI) neuropathic pain rat model, usage of chromic catgut causes intense neuroinflammation and also undesirable conditions such as autotomy. This causes difficulties in the application and interpretation of pain behaviour tests. In this study, it was aimed to investigate the suitability of the use of surgical silk as a suture material in the CCI model, based on behavioural tests and certain biomarkers. Material and Methods: CCI model was created by loosely ligating the right sciatic nerves of rats with surgical silk. Tactile allodynia, thermal and mechanical hyperalgesia were evaluated on the 2nd, 7th, 14th, 21st and 29th postoperative days. Expressions of glial fibrillary acidic protein (GFAP), signal transducer and transcription activator 3 (STAT3) and its phosphorylated form (p-STAT3) were evaluated from the spinal cord tissue by western blotting technique. Results: Sciatic nerve-ligated rats did not lose weight but gained weight on days 14, 21, and 29 like control rats. Statistically significant decreases were found in pain thresholds in three different pain tests after the operation. The decrease in the pain threshold was accompanied by a statistically significant increase in GFAP protein expression in the spinal cord on days 2 and 14 simultaneously. No statistically significant difference was found in the expression of STAT3 or p-STAT3 protein in the spinal cord at any time. Conclusion: The absence of weight loss and autotomy expected from the classical CCI model, the reversal of the decrease in the pain threshold, the concomittant increase in GFAP protein expression in the spinal cord, and the absence of change in STAT3 and p-STAT3 expression in our study suggest that the model we created by tying 3 loose silk knots on the sciatic nerve has a milder course of neuroinflammation.
- Open Access
- 31 October 2022
- Published by Open Exploration Publishing
- Vol. 2 (5) , 226-241
Blockage of thrombospondin 4 secreted by spinal astrocytes may be a promising therapeutic target in the treatment of neuropathic pain
Neuropathic pain (NP), which is difficult to treat, remains a heavy burden for both individuals and society. The efficacy of current treatments is insufficient. The pathophysiology of NP is still not fully elucidated, and there is a need to explore new therapeutic targets to develop more effective treatment strategies. Recent studies showed that thrombospondin 4 (TSP4) protein expression is increased in the spinal cord following nervous system injury and that blocking or inhibiting this increase improves NP. In this review, it has been aimed to present the evidence for the role of TSP4 in the mechanisms of NP development and to evaluate the therapeutic potential of TSP4 blockade in the treatment of NP.
- 31 October 2022
- Published by Open Exploration Publishing
- Vol. 2 (5) , 226-241
Open AccessBlockage of thrombospondin 4 secreted by spinal astrocytes may be a promising therapeutic target in the treatment of neuropathic pain
Neuropathic pain (NP), which is difficult to treat, remains a heavy burden for both individuals and society. The efficacy of current treatments is insufficient. The pathophysiology of NP is still not fully elucidated, and there is a need to explore new therapeutic targets to develop more effective treatment strategies. Recent studies showed that thrombospondin 4 (TSP4) protein expression is increased in the spinal cord following nervous system injury and that blocking or inhibiting this increase improves NP. In this review, it has been aimed to present the evidence for the role of TSP4 in the mechanisms of NP development and to evaluate the therapeutic potential of TSP4 blockade in the treatment of NP.
- Open Access
- 1 January 2022
- Published by Korean Pain Society in The Korean Journal of Pain
- Vol. 35 (1) , 66-77
Effects of cyanocobalamin and its combination with morphine on neuropathic rats and the relationship between these effects and thrombospondin-4 expression
Neslihan Düzenli, Sibel Ülker, Gülgün Şengül, Buse Kayhan, and Aytül Önal. Korean J Pain 2022;35:66-77. https://doi.org/10.3344/kjp.2022.35.1.66
- 1 January 2022
- Published by Korean Pain Society in The Korean Journal of Pain
- Vol. 35 (1) , 66-77
Open AccessEffects of cyanocobalamin and its combination with morphine on neuropathic rats and the relationship between these effects and thrombospondin-4 expression
Neslihan Düzenli, Sibel Ülker, Gülgün Şengül, Buse Kayhan, and Aytül Önal. Korean J Pain 2022;35:66-77. https://doi.org/10.3344/kjp.2022.35.1.66
- Open Access
- 25 October 2019
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 58, 27-33
Hastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı
İnflamatuar nitelikli romatizmal hastalıklarda, analjezikler özellikle de NSAİİ’ler “Hastalığı modifiye eden antiromatizmal ilaçlar (Disease-Modifying Anti-Rheumatic drugs; DMARDs)” ile birlikte sıklıkla kullanılan ilaçlardandır. Söz konusu ilaçlar arasındaki etkileşimler ile ilgili yapılmış kontrollü çalışmalar çok değildir ve daha çok metotreksat ve NSAİİ’ler arasındaki etkileşimler ile ilgilidir. Özellikle son yıllarda kullanımı artan biyolojik DMARD’ler ile analjezik ilaçlar arasındaki etkileşmelere yönelik kontrollü araştırmalara büyük ihtiyaç vardır. Derlememizde, DMARD’ler ile analjezik ilaçlar arasındaki etkileşimler bakımından akılcı ilaç kullanımından söz edilmiştir. Bu etkileşimler, proteine bağlanma, renal, gastrointestinal, hematolojik, hepatik fonksiyonlar ve enzim düzeyindeki değişimler ile ilgili alt başlıklar şeklinde sunulmuştur.
- 25 October 2019
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 58, 27-33
Open AccessHastalığı modifiye eden antiromatizmal ilaçlarla etkileşimler bakımından analjezik ilaçların akılcı kullanımı
İnflamatuar nitelikli romatizmal hastalıklarda, analjezikler özellikle de NSAİİ’ler “Hastalığı modifiye eden antiromatizmal ilaçlar (Disease-Modifying Anti-Rheumatic drugs; DMARDs)” ile birlikte sıklıkla kullanılan ilaçlardandır. Söz konusu ilaçlar arasındaki etkileşimler ile ilgili yapılmış kontrollü çalışmalar çok değildir ve daha çok metotreksat ve NSAİİ’ler arasındaki etkileşimler ile ilgilidir. Özellikle son yıllarda kullanımı artan biyolojik DMARD’ler ile analjezik ilaçlar arasındaki etkileşmelere yönelik kontrollü araştırmalara büyük ihtiyaç vardır. Derlememizde, DMARD’ler ile analjezik ilaçlar arasındaki etkileşimler bakımından akılcı ilaç kullanımından söz edilmiştir. Bu etkileşimler, proteine bağlanma, renal, gastrointestinal, hematolojik, hepatik fonksiyonlar ve enzim düzeyindeki değişimler ile ilgili alt başlıklar şeklinde sunulmuştur.
- 2 March 2011
- Published by Elsevier in Life Sciences
- Vol. 88 (17-18) , 746-752
NADPH-d and Fos reactivity in the rat spinal cord following experimental spinal cord injury and embryonic neural stem cell transplantation
- 2 March 2011
- Published by Elsevier in Life Sciences
- Vol. 88 (17-18) , 746-752
NADPH-d and Fos reactivity in the rat spinal cord following experimental spinal cord injury and embryonic neural stem cell transplantation
- 1 April 2000
- Published by S. Karger AG in Pharmacology
- Vol. 60 (3) , 136-142
Effect of Nabumetone Treatment on Vascular Responses of the Thoracic Aorta in Rat Experimental Arthritis
Nabumetone is a nonsteroidal anti-inflammatory (NSAI) drug which is known to cause less gastrointestinal damage than other NSAI drugs. This study was performed to evaluate whether nabumetone treatment might alter the vascular aberrations related to inflammation in a rat model of adjuvant-induced arthritis. Nabumetone treatment (120 or 240 mg·kg–1·day–1, orally) was initiated on the 15th day of adjuvant inoculation and continued for 14 days. Arthritic lesions, vascular contractile and relaxant responses and gastroduodenal histopathological preparations were evaluated 29 days after adjuvant inoculation. The contractile responses of aortic rings to phenylephrine and KCl were increased in grade 2 arthritic rats. In grade 3 arthritis only the phenylephrine contractility was decreased. The relaxant responses to acetylcholine and sodium nitroprusside were decreased in grades 2 and 3. In healthy rats, nabumetone did not change the vascular responses. After treatment of arthritic rats with nabumetone, both the contractile and relaxant response of the aortic rings returned to normal, and arthritic score and paw swelling were reduced. Gastroduodenal histopathology did not show erosions or ulcers in any of the groups. In conclusion, nabumetone improved the systemic signs and vascular alterations in experimental arthritis without showing any gastrointestinal side effects.
- 1 April 2000
- Published by S. Karger AG in Pharmacology
- Vol. 60 (3) , 136-142
Effect of Nabumetone Treatment on Vascular Responses of the Thoracic Aorta in Rat Experimental Arthritis
Nabumetone is a nonsteroidal anti-inflammatory (NSAI) drug which is known to cause less gastrointestinal damage than other NSAI drugs. This study was performed to evaluate whether nabumetone treatment might alter the vascular aberrations related to inflammation in a rat model of adjuvant-induced arthritis. Nabumetone treatment (120 or 240 mg·kg–1·day–1, orally) was initiated on the 15th day of adjuvant inoculation and continued for 14 days. Arthritic lesions, vascular contractile and relaxant responses and gastroduodenal histopathological preparations were evaluated 29 days after adjuvant inoculation. The contractile responses of aortic rings to phenylephrine and KCl were increased in grade 2 arthritic rats. In grade 3 arthritis only the phenylephrine contractility was decreased. The relaxant responses to acetylcholine and sodium nitroprusside were decreased in grades 2 and 3. In healthy rats, nabumetone did not change the vascular responses. After treatment of arthritic rats with nabumetone, both the contractile and relaxant response of the aortic rings returned to normal, and arthritic score and paw swelling were reduced. Gastroduodenal histopathology did not show erosions or ulcers in any of the groups. In conclusion, nabumetone improved the systemic signs and vascular alterations in experimental arthritis without showing any gastrointestinal side effects.